Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US8557244B1 · kind B1 · utility
53Cited by
52References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 28, 2000 |
| Grant date | Oct 15, 2013 |
| Priority date | — |
| Expiry date | Jul 28, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/801
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.